<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622526</url>
  </required_header>
  <id_info>
    <org_study_id>EMOTION</org_study_id>
    <nct_id>NCT05622526</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis</brief_title>
  <acronym>EMOTION</acronym>
  <official_title>Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer by Capsules vs. Placebo for the Treatment of Patients With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Marqués de Valdecilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EMOTION study is a multicentric, double-blind, controlled, parallel-group, phase IIa&#xD;
      randomized Clinical trial to evaluate the efficacy, safety and tolerability of TMF capsules&#xD;
      for the treatment of patients with NASH.&#xD;
&#xD;
      The clinical trial has two stages:&#xD;
&#xD;
        -  Screening phase with a duration of 12 weeks to classify patients based on lifestyle&#xD;
           modifications.&#xD;
&#xD;
        -  Treatment phase where patients will be randomized and stratified 2:1 to treatment:&#xD;
&#xD;
        -  Experimental for n=64 patients.&#xD;
&#xD;
        -  Placebo control for n=32 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with improvement of fat fraction by proton density by MRI and no worsening of activity or fibrosis.</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with resolution of NASH without worsening of fibrosis.</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with no worsening of fibrosis or activity.</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of adverse events (AEs), serious AEs, AEs resulting in discontinuation of study treatment, AEs of special interest, and changes in vital signs and laboratory values</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (at least one point) in lobular swelling and/or ballooning without worsening of fibrosis.</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAFLD Fibrosis score</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight, BMI.</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic and diastolic blood pressure, lipid profile, carotid ultrasound.</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the quality of life questionnaire specific to chronic liver disease due to NAFLD.</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Patients With Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Group 1 or Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months (4 maintenance doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 or Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months for 12 months (4 maintenance doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1 or Experimental group</intervention_name>
    <description>Capsules of fecal microbiota transplantation</description>
    <arm_group_label>Group 1 or Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group 2 or Control group</intervention_name>
    <description>capsules of placebo</description>
    <arm_group_label>Group 2 or Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both genders aged between 18 and75 years old (both included).&#xD;
&#xD;
          2. Body mass index (BMI) &lt;40 kg/m2.&#xD;
&#xD;
          3. Histological diagnosis of NASH, accepted by EASL and AASLD , from a liver biopsy&#xD;
             obtained up to 24 weeks prior to the signing of the informed consent.&#xD;
&#xD;
          4. NASH histologic activity score (NAS) ≥ 4, with a score of 1 or more in each&#xD;
             subcomponent (steatosis, lobular inflammation, and liver cell ballooning).&#xD;
&#xD;
          5. Histologic evidence of stage 1 fibrosis (with perisinusoidal or portal fibrosis),&#xD;
             stage 2 (perisinusoidal and portal/periportal fibrosis), or stage 3 (bridging&#xD;
             fibrosis) as defined by the NASH CRN fibrosis score.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of other type of liver disease.&#xD;
&#xD;
          2. History of high alcohol intake (daily consumption &gt; 30 g/day for men and &gt; 20 g/day&#xD;
             for women).&#xD;
&#xD;
          3. Weight change of more than 5% in the 3 months prior to screening.&#xD;
&#xD;
          4. Subjects with HbA1c&gt; 9.5%. For subjects with an HbA1c&gt; 9.5% at the screening visit, a&#xD;
             repeat test may be performed within the screening window.&#xD;
&#xD;
             A repeated result of HbA1c&gt; 9.5% will result in exclusion.&#xD;
&#xD;
          5. Diabetic patients with:&#xD;
&#xD;
               -  Insulin treatment.&#xD;
&#xD;
               -  Changes in antidiabetic medication in the 4 months prior to liver biopsy&#xD;
                  according to the following conditions:&#xD;
&#xD;
               -  Modification of the dose of treatment with glucagon agonists type 1 (GLP-1).&#xD;
&#xD;
               -  Implementation of treatment with a new antidiabetic.&#xD;
&#xD;
          6. History of bariatric surgery.&#xD;
&#xD;
          7. Cirrhosis.&#xD;
&#xD;
          8. Portal thrombosis.&#xD;
&#xD;
          9. Known or suspected hepatocellular carcinoma.&#xD;
&#xD;
         10. Clinically significant gastrointestinal, cardiovascular, neurological, psychiatric,&#xD;
             metabolic, renal, hepatic, respiratory, inflammatory or infectious disease, as&#xD;
             determined by the investigator.&#xD;
&#xD;
         11. An estimated glomerular filtration rate (eGFR) &lt;45 ml / min / 1.73 m2 (calculated by&#xD;
             the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] method).&#xD;
&#xD;
         12. Medical conditions that decrease life expectancy to less than 2 years, including&#xD;
             cancer.&#xD;
&#xD;
         13. Presence of an inherited or acquired immunodeficiency.&#xD;
&#xD;
         14. Diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis,&#xD;
             microscopic colitis), active irritable bowel syndrome (within the last 2 years&#xD;
             according to Rome IV criteria), celiac disease not well controlled with a gluten-free&#xD;
             diet, active gastroparesis, toxic megacolon.&#xD;
&#xD;
         15. Major intra-abdominal surgery in the 2 months prior to randomization of the patient in&#xD;
             the study.&#xD;
&#xD;
         16. Antibiotic intake in the 8 weeks prior to the screening date.&#xD;
&#xD;
         17. Probiotic/prebiotic/marketed synbiotic intake in the 4 weeks prior to the screening&#xD;
             date.&#xD;
&#xD;
         18. Pregnancy or lactation.&#xD;
&#xD;
         19. Any other condition that, in the opinion of the investigator, could prevent or hinder&#xD;
             compliance.&#xD;
&#xD;
         20. Use of medication with potential steatogenic effect (corticosteroids, valproic acid,&#xD;
             amiodarone and/or tamoxifen) within the 6 months prior to the first dose of study&#xD;
             drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Javier Crespo</last_name>
    <phone>942315515</phone>
    <email>javiercrespo1991@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Iruzubieta</last_name>
    <phone>942315515</phone>
    <email>paula.iruzubieta@scsalud.es</email>
  </overall_contact_backup>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>September 21, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MetEH: metabolic hepatic steatosis</keyword>
  <keyword>NASH nonalcoholic steatohepatitis</keyword>
  <keyword>TMF: fecal microbiota transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

